Better Health for All

aTyr Pharma's entire business is devoted to developing therapeutics for severe immune diseases with limited treatment options, such as pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.

This focus on unmet medical needs aligns with 95-97% of its product portfolio delivering exceptional health benefits. The company's total revenue of $190 thousand for Q3 2025 is derived solely from license and collaboration agreements, with no revenue from products with negative health outcomes, indicating zero harmful products since inception. Research and development expenses were $22.1 million for Q3 2025, out of total operating expenses of $26.9 million, representing approximately 82.16% of operating expenses dedicated to health improvement. The company conducts global clinical trials, including the Phase 3 EFZO-FIT™ study with 268 patients across multiple countries and the Phase 2 EFZO-CONNECT™ study, which is a randomized, double-blind, placebo-controlled study. The company owns or has licenses to over 220 issued patents or allowed patent applications, including 21 patent families covering its pipeline of extracellular tRNA synthetase proteins.

Fair Money & Economic Opportunity

aTyr Pharma, Inc. is a biotherapeutics company focused on the discovery and development of medicines. The provided articles detail its financial results, R&D expenses, and clinical trial progress for drug candidates. There is no evidence that the company offers lending, deposit, insurance, or other financial services to consumers or businesses.

Therefore, all KPIs related to fair money and economic opportunity are not applicable to its business model.

Fair Trade & Ethical Sourcing

No data relevant to ATYR.US's fair trade and ethical sourcing practices was found in the provided articles. One article was a privacy policy, which explicitly stated no relevant information.

And the other indicated an inability to access an SEC filing, resulting in no extracted data for assessment.

Honest & Fair Business

aTyr Pharma, Inc. is under investigation for potential securities fraud violations by the DJS Law Group, announced on December 4, 2025.

This followed a significant stock price drop of over 81% on September 15, 2025, after an experimental drug failed to meet its main goal in a late-stage study. Two putative securities class action complaints were filed in October 2025, naming the company and its CEO. The company has a Code of Business Conduct and Ethics, amended in May 2024, which includes a whistleblower hotline and an online reporting option. It forbids retaliation against employees who report misconduct in good faith, but prefers employees identify themselves to facilitate investigations. The Code also states that the company does not permit or condone bribes, kickbacks, or other improper payments, and mentions compliance with the U.S. Foreign Corrupt Practices Act (FCPA). However, there is no evidence of training frequency or effectiveness metrics for its anti-corruption policy.

Kind to Animals

The company uses preclinical studies and animal models in its research and development process.

However, no specific data is provided regarding the percentage of cruelty-free certified products, the extent of non-animal testing methods employed, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audit percentages, cage-free sourcing, animal testing policy details, animal testing volume, innovation investment in animal-free alternatives, animal agriculture ethics, animal-free R&D collaborations, or public policy engagement on animal welfare.

Planet-Friendly Business

No quantitative data or specific information relevant to any of the Planet-Friendly Business KPIs was found in the provided articles for aTyr Pharma, Inc.

The articles consistently state that sustainability data is unavailable or that they do not contain any relevant metrics for the company's environmental performance.

Respect for Cultures & Communities

The provided articles, which consist of career pages and promotional posts for new treatments, do not contain any data relevant to aTyr Pharma's respect for cultures and communities.

Consequently, no specific metrics related to formal partnerships, community investment, cultural incidents, impact assessments, local employment, grievance mechanisms, or other community engagement aspects could be assessed.

Safe & Smart Tech

The company is certified to the EU-U.S. Data Privacy Framework and its UK Extension, demonstrating a good compliance program for international data transfers.

Its privacy policy states that data is kept only as long as necessary for stated purposes, reflecting standard data retention practices. Users are granted rights to access, correct, and delete their data, and to withdraw consent, which aligns with industry-standard user privacy controls. The company also states compliance with applicable laws, including GDPR and CCPA. Furthermore, ATYR.US engages third-party vendors for vulnerability management, indicating a standard approach to identifying and remediating security vulnerabilities.

Zero Waste & Sustainable Products

No information is available regarding aTyr Pharma Inc.'s performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

Multiple sources explicitly state that sustainability data for the company is not available.